ATE496059T1 - Oligo-beta-(1,3)-glucan-(1,3)-mannose, oligo-beta-(1,3)-glucan-(1,3)- mannitol und seine derivate zur behandlung von erkrankungen des immunsystems, herstellungsverfahren dafür und wirkstoffe damit - Google Patents

Oligo-beta-(1,3)-glucan-(1,3)-mannose, oligo-beta-(1,3)-glucan-(1,3)- mannitol und seine derivate zur behandlung von erkrankungen des immunsystems, herstellungsverfahren dafür und wirkstoffe damit

Info

Publication number
ATE496059T1
ATE496059T1 AT07872005T AT07872005T ATE496059T1 AT E496059 T1 ATE496059 T1 AT E496059T1 AT 07872005 T AT07872005 T AT 07872005T AT 07872005 T AT07872005 T AT 07872005T AT E496059 T1 ATE496059 T1 AT E496059T1
Authority
AT
Austria
Prior art keywords
beta
glucan
oligo
glucopyranosyl
coch
Prior art date
Application number
AT07872005T
Other languages
English (en)
Inventor
Jean-Claude Yvin
Karine Descroix
Vincent Ferrieres
Frank Jamois
Isabelle Laurent
Vaclav Vetvicka
Original Assignee
Goemar Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goemar Lab Sa filed Critical Goemar Lab Sa
Application granted granted Critical
Publication of ATE496059T1 publication Critical patent/ATE496059T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/08—Deoxysugars; Unsaturated sugars; Osones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
AT07872005T 2006-12-22 2007-12-20 Oligo-beta-(1,3)-glucan-(1,3)-mannose, oligo-beta-(1,3)-glucan-(1,3)- mannitol und seine derivate zur behandlung von erkrankungen des immunsystems, herstellungsverfahren dafür und wirkstoffe damit ATE496059T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611333A FR2910322B1 (fr) 2006-12-22 2006-12-22 Utilisation d'oligo-b-(1,3)-glucanes modifies pour le traite traitement de maladies du systeme immunitaire, oligo-b-(1,3) glucane-(1,3)-mannose, oligo-b-(1,3)-glucane-(1,3)-mannitol et leurs derives, ...
PCT/FR2007/052595 WO2008087340A2 (fr) 2006-12-22 2007-12-20 UTILISATION D' OLIGO-β-(1,3)-GLUCANES MODIFIES POUR LE TRAITEMENT DE MALADIES DU SYSTEME IMMUNITAIRE, OLIGO-β-(1,3)-GLUCANE-(1,3)- MANNOSE, OLIGO-β-(1.3)-GLUCANE-(1,3)- MANNITOL ET LEURS DERIVES, LEURS PROCEDES DE PREPARATION ET MEDICAMENTS LES CONTENANT

Publications (1)

Publication Number Publication Date
ATE496059T1 true ATE496059T1 (de) 2011-02-15

Family

ID=37896020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07872005T ATE496059T1 (de) 2006-12-22 2007-12-20 Oligo-beta-(1,3)-glucan-(1,3)-mannose, oligo-beta-(1,3)-glucan-(1,3)- mannitol und seine derivate zur behandlung von erkrankungen des immunsystems, herstellungsverfahren dafür und wirkstoffe damit

Country Status (12)

Country Link
US (2) US8367641B2 (de)
EP (1) EP2102222B1 (de)
JP (1) JP2010513426A (de)
CN (1) CN101679469A (de)
AT (1) ATE496059T1 (de)
AU (1) AU2007344284B8 (de)
CA (1) CA2674539A1 (de)
DE (1) DE602007012149D1 (de)
FR (1) FR2910322B1 (de)
HK (1) HK1136581A1 (de)
PL (1) PL2102222T3 (de)
WO (1) WO2008087340A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6198207B2 (ja) * 2013-05-15 2017-09-20 国立大学法人群馬大学 新規糖供与体及びそれを用いた糖鎖の合成方法
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
WO2024006582A1 (en) * 2022-07-01 2024-01-04 University Of Virginia Patent Foundation Systems and methods for imaging diverse pathogenic bacteria in vivo with [18f]fluoromannitol positron emission tomography

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2804684A (en) 1955-07-29 1957-09-03 Primo W Talamonti Mustache trimmer
DK131083A (da) * 1982-03-23 1983-09-24 Svenska Sockerfabriks Ab Fremgangsmaade til fremstilling af terapeutiske eller diagnostiske praeparater
JPS5936691A (ja) * 1982-08-24 1984-02-28 Rikagaku Kenkyusho 新規オリゴマンノシド及びその製造法
JPH07100711B2 (ja) * 1986-10-13 1995-11-01 日本ピー・エム・シー株式会社 還元性オリゴ糖のエピ化法
FR2719772B1 (fr) * 1994-05-11 1996-08-02 Goemar Lab Sa Composition cosmétique ou pharmaceutique, notamment dermatologique contenant de la laminarine ou des oligosaccharides dérivés de laminarine.
FR2804684B1 (fr) * 2000-02-04 2002-06-28 Goemar Lab Sa Procede pour la preparation de derives fonctionnalises de beta-(1,3)-glucanes
WO2003045411A2 (de) * 2001-11-26 2003-06-05 Finzelberg Gmbh & Co. Kg Ingwer-extraktzubereitung
US6660722B2 (en) 2001-11-30 2003-12-09 Laboratoires Goemar S.A. Therapeutical treatments
US20050065114A1 (en) * 2003-09-23 2005-03-24 Jean-Claude Yvin Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment
US7070778B2 (en) 2003-10-30 2006-07-04 Laboratoire Goemar Sa Therapeutical combination against cancer

Also Published As

Publication number Publication date
AU2007344284B2 (en) 2013-01-10
FR2910322B1 (fr) 2009-10-30
WO2008087340A3 (fr) 2008-09-18
CA2674539A1 (fr) 2008-07-24
US8367641B2 (en) 2013-02-05
FR2910322A1 (fr) 2008-06-27
US20100286388A1 (en) 2010-11-11
WO2008087340A2 (fr) 2008-07-24
JP2010513426A (ja) 2010-04-30
AU2007344284B8 (en) 2013-01-31
AU2007344284A1 (en) 2008-07-24
EP2102222A2 (de) 2009-09-23
HK1136581A1 (en) 2010-07-02
CN101679469A (zh) 2010-03-24
EP2102222B1 (de) 2011-01-19
PL2102222T3 (pl) 2012-01-31
DE602007012149D1 (de) 2011-03-03
US20130178616A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
EP0522004B1 (de) Verwendung von kupfer enthaltenden wirkstoffen zur beschleunigung der wundheilung
Das et al. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response
DE69909794T2 (de) Verwendung eines dipeptids für wiederherstellungsprozesse
EP2144594A1 (de) Alpha-galactosyl-ceramid-analoga und ihre verwendung als immuntherapie
DE60034865T2 (de) Alloferone - immunomodulierende Peptide
JP2003513012A5 (de)
DE112011102640T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten
ATE496059T1 (de) Oligo-beta-(1,3)-glucan-(1,3)-mannose, oligo-beta-(1,3)-glucan-(1,3)- mannitol und seine derivate zur behandlung von erkrankungen des immunsystems, herstellungsverfahren dafür und wirkstoffe damit
EP1183047B1 (de) Proteinenthaltende pharmazeutische zubereitung
Joseph Giles Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants
Piérard et al. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen
DE69534745T2 (de) Immunopotenzierende 5'-nucleotidase-resistente inosinmonophosphat-derivate und ihre verwendung
Elhawary et al. A trial of doramectin injection and ivermectin spot-on for treatment of rabbits artificially infested with the ear mite “Psoroptes cuniculi”
Putnam et al. Immunosuppression with cyclophosphamide in the dog.
EP0343480A1 (de) Verwendung von Interleukin-2 zur Immunrekonstitution bei abgeschwächter Immunreaktion
JP2004149531A (ja) Ｍｃｐ−１産生抑制剤としてのグリチルリチン及びその誘導体の使用
Ishizuka et al. Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A
DE69618942T2 (de) Derivate und konjugete von mdp, eine von hämatopoitischer funktion stimulierende wirkung und deren enthaltende zusammensetzungen
US20240050398A1 (en) Method against snake envenomation
DE3910011C2 (de)
RU2392929C2 (ru) Средство для стимуляции выброса стволовых кроветворных клеток в кровоток
RU2188003C2 (ru) Способ лечения экспериментальной лепрозной инфекции
Martinelli et al. Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified" TANDEM" transplant program
RU2133616C1 (ru) Иммунотропное средство
DE60215051T2 (de) Zusammensetzung und verfahren zur behandlung chronischer allograft-abstossung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties